Welcome to LookChem.com Sign In|Join Free
  • or
3-bromo-propionic acid-(2-trifluoromethyl-anilide) is a chemical compound that can be described as a derivative of propionic acid, where the propionic acid molecule is modified by the addition of a bromine atom at the third carbon and an anilide group at the second carbon. The anilide group itself is a derivative of aniline, with a trifluoromethyl group attached to the para position (the second carbon) of the benzene ring. 3-bromo-propionic acid-(2-trifluoromethyl-anilide) is characterized by its molecular formula, which includes the bromine, carbon, hydrogen, fluorine, and nitrogen atoms that make up its structure. It is likely to have specific chemical properties and reactivity due to the presence of the bromine and trifluoromethyl groups, which can influence its solubility, stability, and potential applications in various chemical or pharmaceutical processes.

3945-39-9

Post Buying Request

3945-39-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

3945-39-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 3945-39-9 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,9,4 and 5 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 3945-39:
(6*3)+(5*9)+(4*4)+(3*5)+(2*3)+(1*9)=109
109 % 10 = 9
So 3945-39-9 is a valid CAS Registry Number.

3945-39-9Downstream Products

3945-39-9Relevant academic research and scientific papers

Synthesis and Pharmacological Evaluation of Novel C-8 Substituted Tetrahydroquinolines as Balanced-Affinity Mu/Delta Opioid Ligands for the Treatment of Pain

Nastase, Anthony F.,Griggs, Nicholas W.,Anand, Jessica P.,Fernandez, Thomas J.,Harland, Aubrie A.,Trask, Tyler J.,Jutkiewicz, Emily M.,Traynor, John R.,Mosberg, Henry I.

, p. 1840 - 1848 (2018)

The use of opioids for the treatment of pain, while largely effective, is limited by detrimental side effects including analgesic tolerance, physical dependence, and euphoria, which may lead to opioid abuse. Studies have shown that compounds with a μ-opioid receptor (MOR) agonist/δ-opioid receptor (DOR) antagonist profile reduce or eliminate some of these side effects including the development of tolerance and dependence. Herein we report the synthesis and pharmacological evaluation of a series of tetrahydroquinoline-based peptidomimetics with substitutions at the C-8 position. Relative to our lead peptidomimetic with no C-8 substitution, this series affords an increase in DOR affinity and provides greater balance in MOR and DOR binding affinities. Moreover, compounds with carbonyl moieties at C-8 display the desired MOR agonist/DOR antagonist profile whereas alkyl substitutions elicit modest DOR agonism. Several compounds in this series produce a robust antinociceptive effect in vivo and show antinociceptive activity for greater than 2 h after intraperitoneal administration in mice.

Peptidomimetics and Methods of Using the Same

-

Paragraph 0143-0144, (2018/03/25)

Disclosed herein are compounds useful for modulating the mu-opioid receptor (“MOR”) and/or delta-opioid receptor (“DOR”), and methods of using these compounds to treat diseases and conditions, such as pain. In particular, disclosed herein are compounds of

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 3945-39-9